CS MEDICA A/S: CS MEDICA reports Proof of Concept in the results from the clinical trial on NGP-01 (CANNASEN®CBD Psoriasis Gel) against placebo
CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the final efficacy analysis in their clinical trial of CANNASEN®CBD Psoriasis Gel (NGP-01) met all the trial’s primary and secondary efficacy endpoints. Analysis of the data confirms that CANNASEN®CBD Psoriasis Gel (NGP-01) has efficacy in reducing skin pain, Itch, redness, scaling, and the reduction of psoriasis attack of participants with mild-to-moderate psoriasis.The clinical trial data show that the CANNASEN®CBD Psoriasis Gel (NGP-01) shows no adverse effects and is well tolerated and safe. No negative issues have been